Cadila Healthcare had posted a net profit of Rs 543.3 crore in the corresponding period of the previous fiscal, the drug firm said in a filing to BSE.
New Delhi: Cadila Healthcare on Thursday reported six per cent dip in consolidated net profit to Rs 510.7 crore for December quarter 2018, mainly on account of rising in expenses.
It had posted a net profit of Rs 543.3 crore in the corresponding period of the previous fiscal, the drug firm said in a filing to BSE.
Read Also: Cadila Healthcare gets EIR report from USFDA
Total revenue, however, rose to Rs 3,608.9 crore for the latest quarter as against Rs 3,285.6 crore in the same period of 2017-18.
Headquartered at Ahmedabad, the company is a pharmaceutical company in India with INR 54.7 Billion revenue (2015). It is a significant manufacturer of generic drugs.
Cadila was founded in 1952 by Ramanbhai Patel (1925–2001), formerly a lecturer in the L.M. College of Pharmacy, and his business partner Indravadan Modi. It evolved over the next four decades into an established pharmaceutical company